TESARO, Inc. (NASDAQ:TSRO) – Equities research analysts at Jefferies Group increased their Q3 2017 earnings estimates for TESARO in a research report issued to clients and investors on Tuesday. Jefferies Group analyst E. Yang now anticipates that the biopharmaceutical company will earn ($0.66) per share for the quarter, up from their previous forecast of ($2.39). Jefferies Group has a “Hold” rating on the stock. Jefferies Group also issued estimates for TESARO’s Q4 2017 earnings at ($2.54) EPS, FY2017 earnings at ($8.56) EPS, FY2018 earnings at ($7.63) EPS, FY2019 earnings at ($4.48) EPS, FY2020 earnings at $0.32 EPS and FY2021 earnings at $4.76 EPS.

TSRO has been the subject of a number of other reports. BidaskClub lowered TESARO from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Robert W. Baird reaffirmed a “neutral” rating on shares of TESARO in a report on Tuesday, June 6th. Bank of America Corporation reaffirmed a “buy” rating and issued a $154.00 price target on shares of TESARO in a report on Tuesday, June 20th. Wedbush raised TESARO to an “outperform” rating and set a $168.00 price objective for the company in a research note on Monday, June 5th. Finally, ValuEngine lowered TESARO from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $176.35.

WARNING: “TESARO, Inc. (TSRO) Expected to Post Q3 2017 Earnings of ($0.66) Per Share” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/tesaro-inc-tsro-expected-to-post-q3-2017-earnings-of-0-66-per-share/1471781.html.

Shares of TESARO (NASDAQ TSRO) opened at 110.89 on Friday. The stock’s 50 day moving average price is $131.54 and its 200-day moving average price is $149.39. The company’s market capitalization is $5.99 billion. TESARO has a 52-week low of $83.26 and a 52-week high of $192.94.

TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.52) by $0.30. The company had revenue of $29.50 million for the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business’s revenue was down 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.28) earnings per share.

A number of large investors have recently modified their holdings of TSRO. BlackRock Inc. raised its stake in shares of TESARO by 4,504.8% in the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock valued at $524,643,000 after buying an additional 3,335,611 shares during the period. TIAA CREF Investment Management LLC raised its stake in shares of TESARO by 167.9% in the first quarter. TIAA CREF Investment Management LLC now owns 367,519 shares of the biopharmaceutical company’s stock valued at $56,550,000 after buying an additional 230,353 shares during the period. Pioneer Investment Management Inc. raised its stake in shares of TESARO by 195.6% in the second quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock valued at $44,441,000 after buying an additional 210,273 shares during the period. Bank of New York Mellon Corp raised its stake in shares of TESARO by 35.0% in the first quarter. Bank of New York Mellon Corp now owns 675,597 shares of the biopharmaceutical company’s stock valued at $103,954,000 after buying an additional 175,273 shares during the period. Finally, Tobam purchased a new stake in shares of TESARO during the second quarter valued at about $20,189,000.

In other TESARO news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the sale, the vice president now owns 5,396 shares of the company’s stock, valued at $748,155.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 40.50% of the company’s stock.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.